| abstract |
Some modalities of the methods and compositions provided in this document refer to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 receptor (IL13Ra2), cells containing those CARs, and cell-based immunotherapy methods that target cancer cells, such as solid tumor cells. |